{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:56:19Z","timestamp":1792806979625,"version":"4.5.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40265-022-01828-7","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T11:11:20Z","timestamp":1673521880000},"page":"159-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-9093","authenticated-orcid":false,"given":"Niels A. D.","family":"Guchelaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo J.","family":"Noordman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva V. E.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus W. A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra R. M.","family":"Brandt-Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Luyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Bins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd M.","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas P. L.","family":"Wijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron. H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"1828_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(09)60617-6","volume":"374","author":"HH Hartgrink","year":"2009","unstructured":"Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH. Gastric cancer. Lancet. 2009;374:477\u201390.","journal-title":"Lancet"},{"key":"1828_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"1828_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M, Bhatt A, Ceelen W, Glehen O, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7:91.","journal-title":"Nat Rev Dis Primers"},{"key":"1828_CR4","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.3748\/wjg.v22.i30.6829","volume":"22","author":"M Kanda","year":"2016","unstructured":"Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol. 2016;22:6829\u201340.","journal-title":"World J Gastroenterol"},{"key":"1828_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358\u201363.","journal-title":"Cancer"},{"key":"1828_CR6","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.21.02745","volume":"40","author":"YX Gwee","year":"2022","unstructured":"Gwee YX, Chia DKA, So J, Ceelen W, Yong WP, Tan P, et al. Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis. J Clin Oncol. 2022;40:2830.","journal-title":"J Clin Oncol"},{"key":"1828_CR7","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709\u201319.","journal-title":"Lancet Oncol"},{"key":"1828_CR8","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.3390\/jcm10214882","volume":"10","author":"A Rijken","year":"2021","unstructured":"Rijken A, Lurvink RJ, Luyer MDP, Nieuwenhuijzen GAP, van Erning FN, van Sandick JW, et al. The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival. J Clin Med. 2021;10:4882.","journal-title":"J Clin Med"},{"key":"1828_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","volume":"19","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian V, Bhatt A, P\u00e9ron J, Alyami M, Benzerdjeb N, Bakrin N, et al. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol. 2022;19:698\u2013718.","journal-title":"Nat Rev Clin Oncol"},{"key":"1828_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat Res"},{"key":"1828_CR11","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"FF Michael","year":"2005","unstructured":"Michael FF. The transport barrier in intraperitoneal therapy. Am J Physiol Ren Physiol. 2005;288:F433\u201342.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1828_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1001\/jama.1955.02960350004002","volume":"159","author":"AS Weisberger","year":"1955","unstructured":"Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955;159:1704\u20137.","journal-title":"J Am Med Assoc"},{"key":"1828_CR13","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Ren Physiol. 2005;288:F433\u201342.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1828_CR14","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep"},{"key":"1828_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1078155213506244","volume":"20","author":"OM Al-Quteimat","year":"2013","unstructured":"Al-Quteimat OM, Al-Badaineh MA. Intraperitoneal chemotherapy: rationale, applications, and limitations. J Oncol Pharm Pract. 2013;20:369\u201380.","journal-title":"J Oncol Pharm Pract"},{"key":"1828_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","volume":"20","author":"D Kobayashi","year":"2017","unstructured":"Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer. 2017;20:111\u201321.","journal-title":"Gastric Cancer"},{"key":"1828_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-1-4613-1247-5_18","volume":"82","author":"AM Averbach","year":"1996","unstructured":"Averbach AM, Sugarbaker PH. Methodologic considerations in treatment using intraperitoneal chemotherapy. Cancer Treat Res. 1996;82:289\u2013309.","journal-title":"Cancer Treat Res"},{"key":"1828_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/02656736.2017.1401742","volume":"34","author":"PL Feingold","year":"2018","unstructured":"Feingold PL, Klemen ND, Kwong MLM, Hashimoto B, Rudloff U. Adjuvant intraperitoneal chemotherapy for the treatment of colorectal cancer at risk for peritoneal carcinomatosis: a systematic review. Int J Hyperth. 2018;34:501\u201311.","journal-title":"Int J Hyperth"},{"key":"1828_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/bjs.7586","volume":"98","author":"G Matharu","year":"2011","unstructured":"Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011;98:1225\u201335.","journal-title":"Br J Surg"},{"key":"1828_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.22017","volume":"104","author":"RS Gill","year":"2011","unstructured":"Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692\u20138.","journal-title":"J Surg Oncol"},{"key":"1828_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"B de Eelco","year":"2017","unstructured":"de Eelco B, Dimosthenis M, Dimitris S, John R, Odysseas Z. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2:47\u201362.","journal-title":"Pleura Peritoneum."},{"key":"1828_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.critrevonc.2019.01.002","volume":"136","author":"C Marchetti","year":"2019","unstructured":"Marchetti C, De Felice F, Perniola G, Palaia I, Musella A, Di Donato V, et al. Role of intraperitoneal chemotherapy in ovarian cancer in the platinum\u2013taxane-based era: a meta-analysis. Crit Rev Oncol Hematol. 2019;136:64\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1828_CR23","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.21037\/jgo-2020-04","volume":"12","author":"A Brandl","year":"2021","unstructured":"Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. J Gastrointest Oncol. 2021;12:S32\u201344.","journal-title":"J Gastrointest Oncol."},{"key":"1828_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-540-30760-0_4","volume-title":"Advances in peritoneal surface oncology","author":"E de Bree","year":"2007","unstructured":"de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. In: Gonz\u00e1lez-Moreno S, editor. Advances in peritoneal surface oncology. Berlin: Springer; 2007. p. 39\u201351."},{"key":"1828_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4251\/wjgo.v2.i2.109","volume":"2","author":"TD Yan","year":"2010","unstructured":"Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109\u201316.","journal-title":"World J Gastrointest Oncol."},{"key":"1828_CR26","first-page":"53","volume":"169","author":"E de Bree","year":"2007","unstructured":"de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res. 2007;169:53\u201373.","journal-title":"Recent Results Cancer Res"},{"key":"1828_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","volume":"51","author":"C Hasovits","year":"2012","unstructured":"Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet. 2012;51:203\u201324.","journal-title":"Clin Pharmacokinet"},{"key":"1828_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ejso.2006.03.008","volume":"32","author":"E de Bree","year":"2006","unstructured":"de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:666\u201370.","journal-title":"Eur J Surg Oncol"},{"key":"1828_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ctrv.2006.07.006","volume":"32","author":"E de Bree","year":"2006","unstructured":"de Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev. 2006;32:471\u201382.","journal-title":"Cancer Treat Rev"},{"key":"1828_CR30","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.21037\/jgo-2020-03","volume":"12","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH. Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects. J Gastrointest Oncol. 2021;12:S231\u20139.","journal-title":"J Gastrointest Oncol."},{"key":"1828_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062907","volume":"12","author":"JP van Kooten","year":"2022","unstructured":"van Kooten JP, Dietz MV, Guchelaar NAD, Brandt-Kerkhof ARM, Koolen SLW, Burger JWA, et al. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I\/II dose escalation and safety study-INTERACT MESO. BMJ Open. 2022;12: e062907.","journal-title":"BMJ Open"},{"key":"1828_CR32","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis J, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10:1485\u201391.","journal-title":"J Clin Oncol"},{"key":"1828_CR33","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","volume":"13","author":"P Francis","year":"1995","unstructured":"Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol. 1995;13:2961\u20137.","journal-title":"J Clin Oncol"},{"key":"1828_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1006\/gyno.2002.6665","volume":"85","author":"LS Hofstra","year":"2002","unstructured":"Hofstra LS, Bos AME, de Vries EGE, van der Zee AGJ, Willemsen ATM, Rosing H, et al. Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol Oncol. 2002;85:517\u201323.","journal-title":"Gynecol Oncol"},{"key":"1828_CR35","first-page":"2164","volume":"29","author":"S Fushida","year":"2002","unstructured":"Fushida S, Furui N, Kinami S, Ninomiya I, Fujimura T, Nishimura G, et al. Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination. Gan To Kaguku Ryoho. 2002;29:2164\u20137.","journal-title":"Gan To Kaguku Ryoho."},{"key":"1828_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/ejso.2002.1397","volume":"29","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Marchettini P, Stuart OA, Yoo D, Sugarbaker PH. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol. 2003;29:261\u20135.","journal-title":"Eur J Surg Oncol"},{"key":"1828_CR37","first-page":"1","volume-title":"Peritoneal carcinomatosis: drugs and diseases","author":"M Markman","year":"1996","unstructured":"Markman M. Intraperitoneal taxol. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: drugs and diseases. Boston: Springer US; 1996. p. 1\u20135."},{"key":"1828_CR38","first-page":"871","volume":"290","author":"HJ Kuh","year":"1999","unstructured":"Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290:871\u201380.","journal-title":"J Pharmacol Exp Ther"},{"key":"1828_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00280-019-03767-9","volume":"83","author":"MC Cristea","year":"2019","unstructured":"Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, et al. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol. 2019;83:589\u201398.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1828_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00001813-200302000-00003","volume":"14","author":"E de Bree","year":"2003","unstructured":"de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14:103\u201310.","journal-title":"Anticancer Drugs"},{"key":"1828_CR41","first-page":"5896","volume":"9","author":"RJ Morgan Jr","year":"2003","unstructured":"Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res. 2003;9:5896\u2013901.","journal-title":"Clin Cancer Res"},{"key":"1828_CR42","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","volume":"57","author":"FM de Man","year":"2018","unstructured":"de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229\u201354.","journal-title":"Clin Pharmacokinet"},{"key":"1828_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00228-010-0885-3","volume":"66","author":"B-J Ahn","year":"2010","unstructured":"Ahn B-J, Choi MK, Park YS, Lee J, Park SH, Park JO, et al. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. Eur J Clin Pharmacol. 2010;66:1235\u201345.","journal-title":"Eur J Clin Pharmacol"},{"key":"1828_CR44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1055-3207(03)00033-4","volume":"12","author":"A Matsui","year":"2003","unstructured":"Matsui A, Okuda M, Tsujitsuka K, Enomoto K, Maruyama K. Pharmacology of intraperitoneal CPT-11. Surg Oncol Clin N Am. 2003;12:795\u2013811.","journal-title":"Surg Oncol Clin N Am"},{"key":"1828_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00280-010-1272-6","volume":"67","author":"MK Choi","year":"2011","unstructured":"Choi MK, Ahn B-J, Yim D-S, Park YS, Kim S, Sohn TS, et al. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer Chemother Pharmacol. 2011;67:5\u201311.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1828_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-008-0800-0","volume":"63","author":"K Van der Speeten","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009;63:799\u2013805.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1828_CR47","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142:2275\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1828_CR48","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0277-5379(88)90119-8","volume":"24","author":"B Bl\u00f6chl-Daum","year":"1988","unstructured":"Bl\u00f6chl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, et al. Escalating dose regimen of intraperitoneal mitoxantrone: phase I study\u2014clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol. 1988;24:1133\u20138.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"1828_CR49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1055-3207(03)00050-4","volume":"12","author":"KH Link","year":"2003","unstructured":"Link KH, Roitman M, Holtappels M, Runnebaum I, Urbanzyk H, Leder G, et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am. 2003;12:865\u201372 (xvi\u2013xvii).","journal-title":"Surg Oncol Clin N Am"},{"key":"1828_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1525-1438.2006.00846.x","volume":"17","author":"LM Hess","year":"2007","unstructured":"Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. 2007;17:561\u201370.","journal-title":"Int J Gynecol Cancer"},{"key":"1828_CR51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/BF01225271","volume":"118","author":"M Markman","year":"1992","unstructured":"Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547\u201350.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1828_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/026567399285765","volume":"15","author":"M Urano","year":"1999","unstructured":"Urano M. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperth. 1999;15:79\u2013107.","journal-title":"Int J Hyperth"},{"key":"1828_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF00685503","volume":"28","author":"G Los","year":"1991","unstructured":"Los G, Verdegaal EME, Mutsaers PHA, McVie JG. Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159\u201365.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1828_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ygyno.2009.08.028","volume":"115","author":"DD Jandial","year":"2009","unstructured":"Jandial DD, Messer K, Farshchi-Heydari S, Pu M, Howell SB. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol. 2009;115:362\u20136.","journal-title":"Gynecol Oncol"},{"issue":"755\u201369","key":"1828_CR55","first-page":"xiv","volume":"12","author":"DM Elias","year":"2003","unstructured":"Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am. 2003;12(755\u201369):xiv.","journal-title":"Surg Oncol Clin N Am"},{"key":"1828_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267\u201372.","journal-title":"Ann Oncol"},{"key":"1828_CR57","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/SLA.0b013e3182193143","volume":"254","author":"N Pich\u00e9","year":"2011","unstructured":"Pich\u00e9 N, Leblond FA, Sid\u00e9ris L, Pichette V, Drolet P, Fortier L-P, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254:138\u201344.","journal-title":"Ann Surg"},{"key":"1828_CR58","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.1986.4.10.1510","volume":"4","author":"SG Arbuck","year":"1986","unstructured":"Arbuck SG, Trave F, Douglass HO, Nava H, Zakrzewski S, Rustum YM. Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer. J Clin Oncol. 1986;4:1510\u20137.","journal-title":"J Clin Oncol"},{"key":"1828_CR59","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-06-1735","volume":"13","author":"RJ Morgan Jr","year":"2007","unstructured":"Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res. 2007;13:1232\u20137.","journal-title":"Clin Cancer Res"},{"key":"1828_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/890450","volume":"2012","author":"L Bijelic","year":"2012","unstructured":"Bijelic L, Stuart OA, Sugarbaker P. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract. 2012;2012: 890450.","journal-title":"Gastroenterol Res Pract."},{"key":"1828_CR61","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17425247.2018.1446938","volume":"15","author":"S Padmakumar","year":"2018","unstructured":"Padmakumar S, Parayath N, Leslie F, Nair SV, Menon D, Amiji MM. Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. Expert Opin Drug Deliv. 2018;15:481\u201394.","journal-title":"Expert Opin Drug Deliv"},{"key":"1828_CR62","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.21873\/invivo.12811","volume":"36","author":"Y Kumagai","year":"2022","unstructured":"Kumagai Y, Futoh Y, Miyato H, Ohzawa H, Yamaguchi H, Saito S, et al. Effect of systemic or intraperitoneal administration of anti-PD-1 antibody for peritoneal metastases from gastric cancer. In Vivo. 2022;36:1126\u201335.","journal-title":"In Vivo"},{"key":"1828_CR63","doi-asserted-by":"crossref","unstructured":"Jiang T, Zhang H, Li Y, Jayakumar P, Liao H, Huang H, et al. Intraperitoneal injection of class A TLR9 agonist enhances anti-PD-1 immunotherapy in colorectal peritoneal metastases. JCI Insight. 2022;7:e160063.","DOI":"10.1172\/jci.insight.160063"},{"key":"1828_CR64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","volume":"128","author":"PB Burns","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305\u201310.","journal-title":"Plast Reconstr Surg"},{"key":"1828_CR65","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00270-016-1433-z","volume":"39","author":"J Woodley-Cook","year":"2016","unstructured":"Woodley-Cook J, Tarulli E, Tan KT, Rajan DK, Simons ME. Safety and effectiveness of percutaneously inserted peritoneal ports compared to surgically inserted ports in a retrospective study of 87 patients with ovarian carcinoma over a 10-year period. Cardiovasc Intervent Radiol. 2016;39:1629\u201335.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1828_CR66","doi-asserted-by":"crossref","unstructured":"Chia DKA, Sundar R, Kim G, Ang JJ, Lum JHY, Nga ME, et al. Outcomes of a phase II Study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022;29:8597\u20138605.","DOI":"10.1245\/s10434-022-11998-z"},{"key":"1828_CR67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67\u201370.","journal-title":"Ann Oncol"},{"key":"1828_CR68","first-page":"S10","volume":"5","author":"J Kitayama","year":"2012","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S. S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis. Gastrointest Cancer Res. 2012;5:S10\u20133.","journal-title":"Gastrointest Cancer Res."},{"key":"1828_CR69","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.28204","volume":"119","author":"H Yamaguchi","year":"2013","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119:3354\u20138.","journal-title":"Cancer"},{"key":"1828_CR70","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","volume":"28","author":"S Saito","year":"2021","unstructured":"Saito S, Yamaguchi H, Ohzawa H, Miyato H, Kanamaru R, Kurashina K, et al. Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2021;28:3863\u201370.","journal-title":"Ann Surg Oncol"},{"key":"1828_CR71","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1186\/s12885-021-09027-5","volume":"21","author":"M Shi","year":"2021","unstructured":"Shi M, Yang Z, Lu S, Liu W, Ni Z, Yao X, et al. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. BMC Cancer. 2021;21:1344.","journal-title":"BMC Cancer"},{"key":"1828_CR72","doi-asserted-by":"publisher","unstructured":"Tu L, Zhang W, Ni L, Xu Z, Yang K, Gou H, et al. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: a phase II single-arm clinical trial. Cancer Med. 2022. https:\/\/doi.org\/10.1002\/cam4.5277.","DOI":"10.1002\/cam4.5277"},{"key":"1828_CR73","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s10120-017-0710-0","volume":"20","author":"H Cho","year":"2017","unstructured":"Cho H, Ryu MH, Kim KP, Ryoo BY, Park SR, Kim BS, et al. Phase I\/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis. Gastric Cancer. 2017;20:970\u20137.","journal-title":"Gastric Cancer"},{"key":"1828_CR74","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","volume":"71","author":"S Fushida","year":"2013","unstructured":"Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1828_CR75","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.1985.3.7.925","volume":"3","author":"M Markman","year":"1985","unstructured":"Markman M, Cleary S, Lucas WE, Howell SB. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol. 1985;3:925\u201331.","journal-title":"J Clin Oncol"},{"key":"1828_CR76","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1158\/1078-0432.CCR-04-0574","volume":"10","author":"AK Sood","year":"2004","unstructured":"Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, et al. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res. 2004;10:6080\u20135.","journal-title":"Clin Cancer Res"},{"key":"1828_CR77","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/bjs.11792","volume":"107","author":"S Yamada","year":"2020","unstructured":"Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, et al. Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg. 2020;107:1811\u20137.","journal-title":"Br J Surg"},{"key":"1828_CR78","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","volume":"265","author":"S Satoi","year":"2017","unstructured":"Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, et al. Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg. 2017;265:397\u2013401.","journal-title":"Ann Surg"},{"key":"1828_CR79","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","volume":"34","author":"N Takahara","year":"2016","unstructured":"Takahara N, Isayama H, Nakai Y, Ishigami H, Satoi S, Mizuno S, et al. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Investig New Drugs. 2016;34:636\u201342.","journal-title":"Investig New Drugs"},{"key":"1828_CR80","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u20139.","journal-title":"J Clin Oncol"},{"key":"1828_CR81","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13063-022-06143-w","volume":"23","author":"Y Bin","year":"2022","unstructured":"Bin Y, Lan D, Bao W, Yang H, Zhou S, Huang F, et al. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation. Trials. 2022;23:211.","journal-title":"Trials"},{"key":"1828_CR82","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21147\/j.issn.1000-9604.2020.04.07","volume":"32","author":"Z Yang","year":"2020","unstructured":"Yang Z, Li C, Liu W, Zheng Y, Zhu Z, Hua Z, et al. Complications and risk factors for complications of implanted subcutaneous ports for intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis. Chin J Cancer Res. 2020;32:497\u2013507.","journal-title":"Chin J Cancer Res"},{"key":"1828_CR83","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/jjco\/hys129","volume":"42","author":"S Emoto","year":"2012","unstructured":"Emoto S, Ishigami H, Hidemura A, Yamaguchi H, Yamashita H, Kitayama J, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012;42:1013\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"1828_CR84","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138.","journal-title":"Int J Cancer"},{"key":"1828_CR85","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","volume":"24","author":"WJ Koemans","year":"2021","unstructured":"Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24:800\u20139.","journal-title":"Gastric Cancer"},{"key":"1828_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5230\/jgc.2020.20.e6","volume":"20","author":"DW Kim","year":"2020","unstructured":"Kim DW, Jee YS, Kim CH, Kim JJ, Park S, Choi SI, et al. Multicenter retrospective analysis of intraperitoneal paclitaxel and systemic chemotherapy for advanced gastric cancer with peritoneal metastasis. J Gastric Cancer. 2020;20:50\u20139.","journal-title":"J Gastric Cancer."},{"key":"1828_CR87","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000323272","volume":"79","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Yamaguchi H, Yamashita H, Emoto S, et al. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. Oncology. 2010;79:269\u201372.","journal-title":"Oncology"},{"key":"1828_CR88","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000209277","volume":"76","author":"H Ishigami","year":"2009","unstructured":"Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76:311\u20134.","journal-title":"Oncology"},{"key":"1828_CR89","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2152\/jmi.58.134","volume":"58","author":"N Kurita","year":"2011","unstructured":"Kurita N, Shimada M, Iwata T, Nishioka M, Morimoto S, Yoshikawa K, et al. Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study. J Med Investig. 2011;58:134\u20139.","journal-title":"J Med Investig"},{"key":"1828_CR90","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/ajco.13659","volume":"18","author":"S Vatandoust","year":"2021","unstructured":"Vatandoust S, Bright T, Roy AC, Abbas MN, Watson DI, Gan S, et al. Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study). Asia Pac J Clin Oncol. 2021;18:404\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1828_CR91","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000502484","volume":"98","author":"D Kobayashi","year":"2020","unstructured":"Kobayashi D, Ishigami H, Kanda M, Tanaka C, Yamaguchi H, Kitayama J, et al. Phase I study of intraperitoneal administration of paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis. Oncology. 2020;98:48\u201352.","journal-title":"Oncology"},{"key":"1828_CR92","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5230\/jgc.2021.21.e38","volume":"21","author":"D-W Kim","year":"2021","unstructured":"Kim D-W, Seo WJ, Youn SI, Jee YS, Jang Y-J, Kim J-H. Intraperitoneal paclitaxel combined with S-1 plus oxaliplatin for advanced gastric cancer with peritoneal metastasis: a phase I study. J Gastric Cancer. 2021;21:418\u201325.","journal-title":"J Gastric Cancer."},{"key":"1828_CR93","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","volume":"29","author":"SH Kang","year":"2022","unstructured":"Kang SH, Min S-H, Kim JW, Lee E, Park SW, Lee S, et al. Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2022;29:5084\u201391.","journal-title":"Ann Surg Oncol"},{"key":"1828_CR94","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000290955","volume":"78","author":"J Kitayama","year":"2010","unstructured":"Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology. 2010;78:40\u20136.","journal-title":"Oncology"},{"key":"1828_CR95","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1245\/s10434-014-4082-y","volume":"22","author":"S Emoto","year":"2015","unstructured":"Emoto S, Kitayama J, Ishigami H, Yamaguchi H, Watanabe T. Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination. Ann Surg Oncol. 2015;22:780\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1828_CR96","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1369\/0022155417742897","volume":"66","author":"J van Baal","year":"2018","unstructured":"van Baal J, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ, et al. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J Histochem Cytochem. 2018;66:67\u201383.","journal-title":"J Histochem Cytochem"},{"key":"1828_CR97","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.21873\/anticanres.11256","volume":"36","author":"MO Nicoletto","year":"2016","unstructured":"Nicoletto MO, Casarin A, Baldoni A, Rulli E, Tasca G, Baretta Z, et al. Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy. Anticancer Res. 2016;36:6541.","journal-title":"Anticancer Res"},{"key":"1828_CR98","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ygyno.2015.06.026","volume":"138","author":"SE Taylor","year":"2015","unstructured":"Taylor SE, Li R, Petschauer JS, Donovan H, O\u2019Neal S, Keeler AW, et al. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer. Gynecol Oncol. 2015;138:548\u201353.","journal-title":"Gynecol Oncol"},{"key":"1828_CR99","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/ijgc-2018-000055","volume":"29","author":"SE Taylor","year":"2019","unstructured":"Taylor SE, Petschauer JS, Donovan H, Schorzman A, Razo J, Zamboni WC, et al. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer. Int J Gynecol Cancer. 2019;29:147.","journal-title":"Int J Gynecol Cancer"},{"key":"1828_CR100","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Eng J Med. 2018;378:230\u201340.","journal-title":"N Eng J Med"},{"key":"1828_CR101","first-page":"430","volume":"40","author":"CF del Castillo","year":"1993","unstructured":"del Castillo CF, Warshaw L. Peritoneal metastases in pancreatic carcinoma. Hepatogastroenterology. 1993;40:430\u20132.","journal-title":"Hepatogastroenterology"},{"key":"1828_CR102","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MPA.0b013e3182021376","volume":"40","author":"C Morizane","year":"2011","unstructured":"Morizane C, Okusaka T, Morita S, Tanaka K, Ueno H, Kondo S, et al. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas. 2011;40:415\u201321.","journal-title":"Pancreas"},{"key":"1828_CR103","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1634\/theoncologist.2014-0394","volume":"20","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20:143\u201350.","journal-title":"Oncologist"},{"key":"1828_CR104","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10637-020-00982-7","volume":"39","author":"N Takahara","year":"2021","unstructured":"Takahara N, Nakai Y, Ishigami H, Saito K, Sato T, Hakuta R, et al. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Investig New Drugs. 2021;39:175\u201381.","journal-title":"Investig New Drugs"},{"key":"1828_CR105","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.21037\/jgo-20-243","volume":"12","author":"S Yamada","year":"2020","unstructured":"Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, et al. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol. 2020;12:S110\u20137.","journal-title":"J Gastrointest Oncol."},{"key":"1828_CR106","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13063-022-06049-7","volume":"23","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Fujii T, Hirano S, Motoi F, Honda G, Uemura K, et al. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). Trials. 2022;23:119.","journal-title":"Trials"},{"key":"1828_CR107","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","volume":"243","author":"MJ Koppe","year":"2006","unstructured":"Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212\u201322.","journal-title":"Ann Surg"},{"key":"1828_CR108","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/309417","volume":"2012","author":"PH Sugarbaker","year":"2012","unstructured":"Sugarbaker PH. Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? Gastroenterol Res Pract. 2012;2012: 309417.","journal-title":"Gastroenterol Res Pract."},{"key":"1828_CR109","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00280-018-3714-5","volume":"83","author":"K Murono","year":"2019","unstructured":"Murono K, Nagata H, Ishimaru K, Emoto S, Kaneko M, Hiyoshi M, et al. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. Cancer Chemother Pharmacol. 2019;83:145\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1828_CR110","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00384-020-03649-0","volume":"35","author":"K Murono","year":"2020","unstructured":"Murono K, Nozawa H, Nagata H, Ishimaru K, Sonoda H, Emoto S, et al. Efficacy of intraperitoneally administered paclitaxel forcolorectal cancer with peritoneal metastases. Int J Colorectal Dis. 2020;35:1945\u20139.","journal-title":"Int J Colorectal Dis"},{"key":"1828_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034508","volume":"9","author":"NL de Boer","year":"2019","unstructured":"de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Diepeveen M, van Meerten E, van Eerden RAG, et al. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial. BMJ Open. 2019;9: e034508.","journal-title":"BMJ Open"},{"key":"1828_CR112","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5:8.","journal-title":"Ann Transl Med."},{"key":"1828_CR113","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1245\/s10434-019-07803-z","volume":"26","author":"NL de Boer","year":"2019","unstructured":"de Boer NL, van Kooten JP, Damhuis RAM, Aerts JGJV, Verhoef C, Madsen EVE. Malignant peritoneal mesothelioma: patterns of care and survival in the Netherlands: a population-based study. Ann Surg Oncol. 2019;26:4222\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1828_CR114","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1081\/CNV-120023766","volume":"21","author":"DT Le","year":"2003","unstructured":"Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Investig. 2003;21:682\u20139.","journal-title":"Cancer Investig"},{"key":"1828_CR115","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ctrv.2006.11.001","volume":"33","author":"RM Smeenk","year":"2007","unstructured":"Smeenk RM, Verwaal VJ, Zoetmulder FA. Pseudomyxoma peritonei. Cancer Treat Rev. 2007;33:138\u201345.","journal-title":"Cancer Treat Rev"},{"key":"1828_CR116","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368\u201377.","journal-title":"Lancet Oncol"},{"key":"1828_CR117","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","volume":"140","author":"F Dumont","year":"2020","unstructured":"Dumont F, Passot C, Raoul JL, Kepenekian V, Leli\u00e8vre B, Boisdron-Celle M, et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur J Cancer. 2020;140:37\u201344.","journal-title":"Eur J Cancer"},{"key":"1828_CR118","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/cancers13051060","volume":"13","author":"M Robella","year":"2021","unstructured":"Robella M, De Simone M, Berchialla P, Argenziano M, Borsano A, Ansari S, et al. A phase I dose escalation study of oxaliplatin, cisplatin and doxorubicin applied as PIPAC in patients with peritoneal carcinomatosis. Cancers (Basel). 2021;13:1060.","journal-title":"Cancers (Basel)."},{"key":"1828_CR119","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-20-2152","volume":"27","author":"G Kim","year":"2021","unstructured":"Kim G, Tan HL, Sundar R, Lieske B, Chee CE, Ho J, et al. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res. 2021;27:1875\u201381.","journal-title":"Clin Cancer Res"},{"key":"1828_CR120","doi-asserted-by":"publisher","first-page":"104151","DOI":"10.1016\/j.ebiom.2022.104151","volume":"82","author":"W Ceelen","year":"2022","unstructured":"Ceelen W, Sandra L, de Sande LV, Graversen M, Mortensen MB, Vermeulen A, et al. Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases. EBioMedicine. 2022;82:104151.","journal-title":"EBioMedicine"},{"key":"1828_CR121","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","volume":"137","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol. 2015;137:223\u20138.","journal-title":"Gynecol Oncol"},{"key":"1828_CR122","doi-asserted-by":"publisher","first-page":"175883591984640","DOI":"10.1177\/1758835919846402","volume":"11","author":"F Struller","year":"2019","unstructured":"Struller F, Horvath P, Solass W, Weinreich F-J, Strumberg D, Kokkalis MK, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402.","journal-title":"Ther Adv Med Oncol."},{"key":"1828_CR123","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/pp-2016-0017","volume":"1","author":"V Khomyakov","year":"2016","unstructured":"Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1:159\u201366.","journal-title":"Pleura Peritoneum."},{"key":"1828_CR124","doi-asserted-by":"crossref","unstructured":"Rovers KP, Wassenaar ECE, Lurvink RJ, Creemers G-JM, Burger JWA, Los M, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC). Ann Surg Oncol. 2021;28:5311\u201326.","DOI":"10.1245\/s10434-020-09558-4"},{"key":"1828_CR125","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/biomedicines8050102","volume":"8","author":"M De Simone","year":"2020","unstructured":"De Simone M, Vaira M, Argenziano M, Berchialla P, Pisacane A, Cinquegrana A, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, phase II clinical trial. Biomedicines. 2020;8:102.","journal-title":"Biomedicines."},{"key":"1828_CR126","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47:123\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"1828_CR127","doi-asserted-by":"publisher","first-page":"e0186709-e","DOI":"10.1371\/journal.pone.0186709","volume":"12","author":"T Khosrawipour","year":"2017","unstructured":"Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS ONE. 2017;12:e0186709-e.","journal-title":"PLoS ONE"},{"key":"1828_CR128","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5230\/jgc.2018.18.e37","volume":"18","author":"I Gockel","year":"2018","unstructured":"Gockel I, Jansen-Winkeln B, Haase L, Rhode P, Mehdorn M, Niebisch S, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study. J Gastric Cancer. 2018;18:379\u201391.","journal-title":"J Gastric Cancer."},{"key":"1828_CR129","doi-asserted-by":"publisher","first-page":"175883591877703","DOI":"10.1177\/1758835918777036","volume":"10","author":"M Graversen","year":"2018","unstructured":"Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1758835918777036.","journal-title":"Ther Adv Med Oncol."},{"key":"1828_CR130","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10585-018-9925-7","volume":"35","author":"P Horvath","year":"2018","unstructured":"Horvath P, Beckert S, Struller F, K\u00f6nigsrainer A, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer. Clin Exp Metastasis. 2018;35:635\u201340.","journal-title":"Clin Exp Metastasis"},{"key":"1828_CR131","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0300891619868013","volume":"106","author":"I Gockel","year":"2020","unstructured":"Gockel I, Jansen-Winkeln B, Haase L, Niebisch S, Moulla Y, Lyros O, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori. 2020;106:70\u20138.","journal-title":"Tumori"},{"key":"1828_CR132","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1245\/s10434-021-10860-y","volume":"29","author":"R Sindayigaya","year":"2022","unstructured":"Sindayigaya R, Dogan C, Demtr\u00f6der CR, Fischer B, Karam E, Buggisch JR, et al. Clinical outcome for patients managed with low-dose cisplatin and doxorubicin delivered as pressurized intraperitoneal aerosol chemotherapy for unresectable peritoneal metastases of gastric cancer. Ann Surg Oncol. 2022;29:112\u201323.","journal-title":"Ann Surg Oncol"},{"key":"1828_CR133","doi-asserted-by":"publisher","first-page":"2743985","DOI":"10.1155\/2018\/2743985","volume":"2018","author":"F Kurtz","year":"2018","unstructured":"Kurtz F, Struller F, Horvath P, Solass W, B\u00f6sm\u00fcller H, K\u00f6nigsrainer A, et al. Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroenterol Res Pract. 2018;2018:2743985.","journal-title":"Gastroenterol Res Pract."},{"key":"1828_CR134","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","volume":"43","author":"M Alyami","year":"2017","unstructured":"Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:2178\u201383.","journal-title":"Eur J Surg Oncol"},{"key":"1828_CR135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.21037\/jgo.2015.11.02","volume":"7","author":"RN Low","year":"2016","unstructured":"Low RN. Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7:58\u201371.","journal-title":"J Gastrointest Oncol."},{"key":"1828_CR136","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s00259-020-05146-6","volume":"48","author":"L Zhao","year":"2021","unstructured":"Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [(68)Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [(18)F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:1944\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01828-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T07:53:06Z","timestamp":1676101986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01828-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1828"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01828-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"12 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bas P.L. Wijnhoven received consulting fees and a research grant from BMS. Bianca Mostert received consulting fees from Lilly, Servier and BMS, and research funding from Sanofi, Pfizer and BMS. Niels A.D. Guchelaar, Bo J. Noordman, Stijn L.W. Koolen, Eva V.E. Madsen, Jacobus W.A. Burger, Alexandra R.M. Brandt-Kerkhof, Geert-Jan Creemers, Ignace H.J.T. de Hingh, Misha Luyer, Sander Bins, Esther van Meerten, Sjoerd M. Lagarde, Cornelis Verhoef and Ron. H.J. Mathijssen declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NADG: conceptualization, methodology, validation, investigation, data curation, writing\u2014original draft, writing\u2014review and editing, visualization, project administration. BJN: conceptualization, methodology, validation, investigation, data curation, writing\u2014original draft, writing\u2014review and editing, visualization, project administration. SLWK: conceptualization, methodology, supervision, writing\u2014review and editing. BM: conceptualization, methodology, supervision, writing\u2014review and editing. EVEM: writing\u2014review and editing. JWAB: writing\u2014review and editing. ARMB-K: writing\u2014review and editing. G-JC: writing\u2014review and editing. IHJTdH: writing\u2014review and editing. ML: writing\u2014review and editing. SB: writing\u2014review and editing. EvM: writing\u2014review and editing. SML: writing\u2014review and editing. CV: writing\u2014review and editing. BPLW: conceptualization, methodology, supervision, writing\u2014review and editing. RHJM: conceptualization, methodology, supervision, writing\u2014review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}